Stefan James

Summary

Affiliation: Uppsala University Hospital
Country: Sweden

Publications

  1. doi request reprint Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack
    Stefan K James
    Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
    Circulation 125:2914-21. 2012
  2. pmc P2Y12 platelet inhibition in clinical practice
    Peter Damman
    Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Thromb Thrombolysis 33:143-53. 2012
  3. doi request reprint Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial
    Stefan James
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    Circulation 122:1056-67. 2010
  4. pmc Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan James
    Uppsala Clinical Research Center, Uppsala University, Dag Hammarsköldsväg 14B, Science Park, Uppsala SE 751 85, Sweden
    Eur Heart J 31:3006-16. 2010
  5. pmc Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan K James
    Uppsala Clinical Research Center, Uppsala University, Sweden
    BMJ 342:d3527. 2011
  6. ncbi request reprint Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease
    Oscar O Braun
    Department of Medical Sciences, Clinical Chemistry, Akademiska Hospital, Uppsala, Sweden
    Thromb Haemost 100:626-33. 2008
  7. doi request reprint Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
    Christoph Varenhorst
    Uppsala Clinical Research Center, Department Medical Sciences and Cardiology, Uppsala University, Sweden
    Am Heart J 157:562.e1-9. 2009
  8. doi request reprint Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
    David Erlinge
    Department of Cardiology, Lund University, Lund, Sweden
    J Am Coll Cardiol 52:1968-77. 2008
  9. doi request reprint Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Lars Wallentin
    Uppsala Clinical Research Center, Uppsala, Sweden
    N Engl J Med 361:1045-57. 2009
  10. doi request reprint Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
    Lars Wallentin
    Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
    Lancet 376:1320-8. 2010

Detail Information

Publications29

  1. doi request reprint Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack
    Stefan K James
    Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
    Circulation 125:2914-21. 2012
    ..Patients with acute coronary syndromes and history of stroke or transient ischemic attack (TIA) have an increased rate of recurrent cardiac events and intracranial hemorrhages...
  2. pmc P2Y12 platelet inhibition in clinical practice
    Peter Damman
    Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Thromb Thrombolysis 33:143-53. 2012
    ....
  3. doi request reprint Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial
    Stefan James
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    Circulation 122:1056-67. 2010
    ....
  4. pmc Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan James
    Uppsala Clinical Research Center, Uppsala University, Dag Hammarsköldsväg 14B, Science Park, Uppsala SE 751 85, Sweden
    Eur Heart J 31:3006-16. 2010
    ..We aimed to investigate the outcome with ticagrelor vs. clopidogrel in patients with DM or poor glycaemic control...
  5. pmc Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan K James
    Uppsala Clinical Research Center, Uppsala University, Sweden
    BMJ 342:d3527. 2011
    ..To evaluate efficacy and safety outcomes in patients in the PLATelet inhibition and patient Outcomes (PLATO) trial who at randomisation were planned for a non-invasive treatment strategy...
  6. ncbi request reprint Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease
    Oscar O Braun
    Department of Medical Sciences, Clinical Chemistry, Akademiska Hospital, Uppsala, Sweden
    Thromb Haemost 100:626-33. 2008
    ..Attenuated platelet aggregation and reduced expression of platelet pro-coagulant and pro-inflammatory markers with prasugrel suggest the potential to reduce cardiovascular events both in the acute setting and in long-term treatment...
  7. doi request reprint Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
    Christoph Varenhorst
    Uppsala Clinical Research Center, Department Medical Sciences and Cardiology, Uppsala University, Sweden
    Am Heart J 157:562.e1-9. 2009
    ..These tests need to be evaluated in comparison to reference measurements of P2Y(12) function during different thienopyridine treatments...
  8. doi request reprint Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
    David Erlinge
    Department of Cardiology, Lund University, Lund, Sweden
    J Am Coll Cardiol 52:1968-77. 2008
    ..We evaluated the prevalence and mechanism of poor responsiveness to clopidogrel and prasugrel in coronary artery disease patients with and without diabetes...
  9. doi request reprint Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Lars Wallentin
    Uppsala Clinical Research Center, Uppsala, Sweden
    N Engl J Med 361:1045-57. 2009
    ..Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel...
  10. doi request reprint Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
    Lars Wallentin
    Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
    Lancet 376:1320-8. 2010
    ..CYP2C19 and ABCB1 genotypes are known to influence the effects of clopidogrel. In this substudy, we investigated the effects of these genotypes on outcomes between and within treatment groups...
  11. pmc Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
    Christoph Varenhorst
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
    Eur Heart J 30:1744-52. 2009
    ..We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel...
  12. doi request reprint Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan James
    Uppsala Clinical Research Center, Sweden
    Am Heart J 157:599-605. 2009
    ....
  13. doi request reprint Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery
    Christoph Varenhorst
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
    J Am Coll Cardiol 60:1623-30. 2012
    ..This study investigated the differences in specific causes of post-coronary artery bypass graft surgery (CABG) deaths in the PLATO (Platelet Inhibition and Patient Outcomes) trial...
  14. doi request reprint Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Sasha Koul
    Department of Cardiology, Lund University, Skane University Hospital, Sweden
    Eur Heart J 32:2989-97. 2011
    ....
  15. doi request reprint Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study
    Christoph Varenhorst
    Uppsala Clinical Research Center, Department of Medical Sciences, Cardiology, Uppsala University, Sweden
    Am Heart J 162:363-71. 2011
    ..On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls...
  16. doi request reprint Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?
    Christoph Varenhorst
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
    Curr Cardiol Rep 14:486-92. 2012
    ..This review provides recommendations for their optimal use...
  17. doi request reprint Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registr
    Michael Koutouzis
    Department of Cardiology, Sahlgrenska University Hospital, 4 Bruna straket, 41345 Gothenburg, Sweden
    Heart 97:1484-8. 2011
    ..However, the effect of adding UFH in patients with ST elevation myocardial infarction (STEMI) treated with bivalirudin during primary PCI is unknown...
  18. pmc New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
    Jonas Oldgren
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Eur Heart J 34:1670-80. 2013
    ....
  19. doi request reprint Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
    Giovanna Sarno
    Department of Medical Sciences, Cardiology, Uppsala University Uppsala, Uppsala, Sweden
    Int J Cardiol 167:146-50. 2013
    ..The aim of this study was to describe the initial clinical experience with the everolimus eluting platinum chromium stent (Promus Element) in unselected patients from a real life nationwide registry...
  20. doi request reprint Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
    Giovanna Sarno
    Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
    Eur Heart J 33:606-13. 2012
    ..To compare the long-term outcome after percutaneous coronary intervention with 'new-generation' drug-eluting stents (n-DES) to 'older generation' DES (o-DES), and bare-metal stents (BMS) in a real-world population...
  21. doi request reprint The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes
    Bertil Lindahl
    Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, University of Uppsala, Uppsala, Sweden
    Am Heart J 160:224-9. 2010
    ..However, how the hs-cTnT assay compares with the old cTnT assay for risk assessment in ACS is still unknown...
  22. ncbi request reprint Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial
    Stefan James
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Am J Med 115:178-84. 2003
    ..However, the appropriate cutoff for identifying patients with the acute coronary syndrome who are at low risk of subsequent mortality has not been established...
  23. doi request reprint Prognostic implications of changes in cardiac troponin I levels in patients with non-ST elevation acute coronary syndrome
    Kai M Eggers
    Cardiology Unit, Department of Medical Sciences, Faculty of Medicine, Uppsala University, Uppsala, Sweden and
    Biomarkers 18:668-72. 2013
    ..Information is limited on the prognostic implications of cardiac troponin I (cTnI) changes during the first days of non-ST elevation acute coronary syndrome (NSTE-ACS)...
  24. doi request reprint The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART)
    Tomas Jernberg
    Department of Cardiology, Karolinska University Hospital, Huddinge, Institution of Medicine H7, Huddinge, Karolinska Institutet, Stockholm 141 86, Sweden
    Heart 96:1617-21. 2010
    ....
  25. ncbi request reprint Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
    Lars Wallentin
    Department of Medical Sciences and Cardiology, Uppsala Clinical Research Center, University Hospital, 751 85 Uppsala, Sweden
    Eur Heart J 29:21-30. 2008
    ..P2Y(12) receptor antagonism and platelet inhibition by prasugrel vs. clopidogrel were investigated in patients with stable coronary artery disease...
  26. ncbi request reprint Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin
    Stefan James
    Department of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Ups J Med Sci 109:71-122. 2004
    ..Any detectable elevation of TnT and reduced creatinine clearance, but neither elevation of CRP nor NT-proBNP, were also independently associated to a raised risk of subsequent myocardial infarction...
  27. doi request reprint Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia
    Per Venge
    Department of Medical Sciences, University of Uppsala, Sweden
    J Am Coll Cardiol 54:1165-72. 2009
    ..This study sought to evaluate the analytical and clinical performance of the novel hypersensitive cardiac troponin I (cTnI) prototype assay from Beckman Coulter (Fullerton, California)...
  28. ncbi request reprint The antibody configurations of cardiac troponin I assays may determine their clinical performance
    Stefan James
    Department of Medical Sciences, Cardiology, Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden
    Clin Chem 52:832-7. 2006
    ..The approach has been adopted by the new cTnI assay from Abbott Diagnostics. The aim of our study was to investigate whether this approach affects the clinical performance of cTnI assays...
  29. ncbi request reprint Diagnostic applications of natriuretic peptides in ischemic heart disease
    Bertil Lindahl
    University Hospital of Uppsala, Uppsala, Sweden
    Heart Fail Clin 2:311-21. 2006